Impact of poisonous snake bite on the health status by understanding the changes happening after the bite.
Phase 4
- Conditions
- Health Condition 1: T630- Toxic effect of snake venom
- Registration Number
- CTRI/2019/07/020006
- Lead Sponsor
- Science and Engineering Research Board
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Hematotoxic snake bites
2. Specified age group
3. Patients admitted on the day of bite
Exclusion Criteria
1. Patients who do not want to participate in the study.
2. Patients who are discharged after 48 hours or who obtain discharge against medical advices.
3. Pregnant females.
4. Patients who are diagnosed cases of bleeding disorders or on anti platelet drugs and oral anticoagulant
5. Treated outside hospitals
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Analysis of the serum ADMATS 13 level and Complement Factor H activity to understand the pathophysiology of TMA in these patients. 2.Comparison of cellular microparticle concentration between the two groups to understand the clinical implications of these microparticles in snakebite associated TMA. 3.Establishing the correlation between these parameters and the clinical outcome of the patient whether they a play any role on patient�s prognosis.Timepoint: A) 0-6 months - Establishing the Flow cytometry and ELISA tests. <br/ ><br>B) 6 months to 36 months - Enrolling of patients and sample collections and clinical monitoring. <br/ ><br>C) 6months to 36 months - Flow cytometry analysis of cell derived microparticles. <br/ ><br>D) 24 months to 36 months - ELISA testing for ADAMTS 13, Complement Factor H proteins. <br/ ><br>E) 30 months - 36 months - Data analysis and manuscript completion
- Secondary Outcome Measures
Name Time Method 1.Effect of TMA on the prognosis will be assessed by the length of hospital stay, interventions like hemodialysis and blood transfusion received, complications and 30 days mortality. 2.Complication rates across both the groups will be analysed to identify the role of TMA in the clinical course of the disease.Timepoint: 6months - 30 months